{"id":12256,"date":"2024-10-18T17:34:21","date_gmt":"2024-10-18T15:34:21","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=12256"},"modified":"2026-03-03T10:32:02","modified_gmt":"2026-03-03T09:32:02","slug":"medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/","title":{"rendered":"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique"},"content":{"rendered":"\n<p class=\"is-style-paragraph-lead-text\">La Commission de la sant\u00e9 du Conseil national s\u2019est prononc\u00e9e pour l\u2019introduction de mod\u00e8les d\u2019impact budg\u00e9taire pour les m\u00e9dicaments innovants. Dans le d\u00e9bat sur la ma\u00eetrise des co\u00fbts dans le syst\u00e8me de sant\u00e9, c\u2019est donc \u00e0 nouveau l\u2019industrie pharmaceutique pratiquant la recherche qui fait les frais d\u2019\u00e9conomies douloureuses. Interpharma est n\u00e9anmoins dispos\u00e9e \u00e0 continuer de contribuer de mani\u00e8re constructive \u00e0 la recherche de solutions, de mani\u00e8re \u00e0 \u00e9viter une nouvelle d\u00e9gradation de l\u2019acc\u00e8s des patientes et patients aux nouveaux m\u00e9dicaments modernes, souvent vitaux. <\/p>\n\n\n\n<p>Dans le cadre des d\u00e9bats sur les modifications de la LAMal, 2<sup>e<\/sup> volet de mesures visant \u00e0 freiner la hausse des co\u00fbts (2<sup>e<\/sup> volet), la Commission de la sant\u00e9 du Conseil national (CSSS-N) a d\u00e9cid\u00e9 d\u2019introduire ce que l\u2019on appelle des mod\u00e8les d\u2019impact budg\u00e9taire. Ces rabais sur les m\u00e9dicaments innovants en fonction du volume de march\u00e9 avaient auparavant \u00e9t\u00e9 introduits dans le projet par le Conseil des \u00c9tats sans consultations pr\u00e9alables et ils impliquent une profonde modification du syst\u00e8me de formation des prix. Lors de sa s\u00e9ance du 16&nbsp;ao\u00fbt 2024, la CSSS-N avait donc d\u00e9cid\u00e9 de laisser au groupe de travail form\u00e9 de l\u2019OFSP, des assureurs-maladie et de l\u2019industrie plus de temps pour r\u00e9gler les nombreuses questions de mise en \u0153uvre encore en suspens. Depuis, le groupe de travail a avanc\u00e9 sur plusieurs points, mais les travaux ne sont pas encore achev\u00e9s.<\/p>\n\n\n\n<p>Le fait que la CSSS-N ancre n\u00e9anmoins d\u00e8s \u00e0 pr\u00e9sent les mod\u00e8les d\u2019impact budg\u00e9taire est une c\u00e9sure pour l\u2019industrie pharmaceutique. La p\u00e9riode de transition fix\u00e9e \u00e0 deux ans est trop courte, met en danger la s\u00e9curit\u00e9 juridique et la pr\u00e9visibilit\u00e9 pour les entreprises et affaiblit une fois de plus l\u2019attrait du petit march\u00e9 suisse. Tout au moins la CSSS-N a-t-elle d\u00e9cid\u00e9 que ces mod\u00e8les devraient \u00eatre fix\u00e9s individuellement et en tenant compte des sp\u00e9cificit\u00e9s des produits. Nous saluons cette modification importante. Interpharma demande aussi \u00e0 l\u2019administration de se conformer aux promesses qu\u2019elle a faites lors de plusieurs r\u00e9unions au sujet de la modification des ordonnances ainsi que de proc\u00e9der s\u00e9rieusement, en coop\u00e9ration avec les acteurs concern\u00e9s, \u00e0 la modernisation urgente du syst\u00e8me de formation des prix des m\u00e9dicaments. Le temps presse car, comme le montrent plusieurs \u00e9tudes actuelles, l\u2019obsolescence du syst\u00e8me est largement responsable de la d\u00e9gradation galopante de l\u2019approvisionnement des patient-e-s de Suisse en m\u00e9dicaments innovants.<a id=\"_ftnref1\" href=\"#_ftn1\">[1]<\/a> <a id=\"_ftnref2\" href=\"#_ftn2\">[2]<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-freiner-la-hausse-des-couts-ce-n-est-pas-sauver-des-vies\">Freiner la hausse des co\u00fbts, ce n\u2019est pas sauver des vies<\/h2>\n\n\n\n<p><em>\u00abLes entreprises pharmaceutiques pratiquant la recherche en Suisse s\u2019engagent pour un syst\u00e8me de sant\u00e9 adapt\u00e9 \u00e0 l\u2019avenir et p\u00e9renne. L\u2019introduction de mod\u00e8les d\u2019impact budg\u00e9taire signifie que la branche contribue \u00e0 nouveau \u00e0 des \u00e9conomies consid\u00e9rables. Interpharma appelle le Parlement et le Conseil f\u00e9d\u00e9ral \u00e0 assumer quant \u00e0 eux leurs responsabilit\u00e9s en mati\u00e8re d\u2019acc\u00e8s des patientes et patients \u00e0 des m\u00e9dicaments souvent vitaux. Se contenter de freiner la hausse des co\u00fbts, ce n\u2019est pas sauver des vies.\u00bb <\/em>Ren\u00e9 Buholzer, directeur d\u2019Interpharma<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-le-conseil-national-doit-rectifier-a-la-session-d-automne\">Le Conseil national doit rectifier \u00e0 la session d\u2019automne<\/h2>\n\n\n\n<p>D\u2019apr\u00e8s des estimations, les mod\u00e8les d\u2019impact budg\u00e9taire et les autres mesures d\u00e9cid\u00e9es au sujet des m\u00e9dicaments dans le cadre du 2<sup>e<\/sup> volet devraient entra\u00eener plusieurs centaines de millions de francs d\u2019\u00e9conomies dans le syst\u00e8me de sant\u00e9. Ceci en suppl\u00e9ment des \u00e9conomies de plus de 1.5 milliard de francs d\u00e9j\u00e0 r\u00e9alis\u00e9es ann\u00e9e apr\u00e8s ann\u00e9e par le biais des baisses de prix r\u00e9guli\u00e8res des m\u00e9dicaments par l\u2019OFSP, ainsi que de nombreuses autres mesures prises aux d\u00e9pens des entreprises pharmaceutiques pratiquant la recherche.<\/p>\n\n\n\n<p>Interpharma appelle le Conseil f\u00e9d\u00e9ral et le Parlement \u00e0 ne pas affaiblir encore plus l\u2019acc\u00e8s des patient-e-s et la s\u00e9curit\u00e9 d\u2019approvisionnement en m\u00e9dicaments en Suisse. \u00c0 cet \u00e9gard, il est d\u00e9cisif que le pl\u00e9num du Conseil national suive en d\u00e9cembre la minorit\u00e9 de la Commission et proc\u00e8de \u00e0 des rectifications au sujet de la semi-confidentialit\u00e9 des mod\u00e8les de prix ainsi que de l\u2019acc\u00e8s d\u00e8s le \u00abjour 0\u00bb aux m\u00e9dicaments soumis \u00e0 ordonnance m\u00e9dicale.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ftnref1\" id=\"_ftn1\">[1]<\/a> <a href=\"https:\/\/www.interpharma.ch\/blog\/communique-de-presse-lapprovisionnement-en-medicaments-est-en-danger-le-marche-suisse-perd-de-son-attrait\/?lang=fr\">Communiqu\u00e9 de presse &#8211; L\u2019approvisionnement en m\u00e9dicaments est en danger: le march\u00e9 suisse perd de son attrait &#8211; Interpharma<\/a><\/p>\n\n\n\n<p><a href=\"#_ftnref2\" id=\"_ftn2\">[2]<\/a> <a href=\"https:\/\/www.interpharma.ch\/blog\/communique-de-presse-disponibilite-des-medicaments-la-suisse-perd-du-terrain\/?lang=fr\">Communiqu\u00e9 de presse: Disponibilit\u00e9 des m\u00e9dicaments: la Suisse perd du terrain &#8211; Interpharma<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Commission de la sant\u00e9 du Conseil national s\u2019est prononc\u00e9e pour l\u2019introduction de mod\u00e8les d\u2019impact budg\u00e9taire pour les m\u00e9dicaments innovants. Dans le d\u00e9bat sur la ma\u00eetrise des co\u00fbts dans le syst\u00e8me de sant\u00e9, c\u2019est donc \u00e0 nouveau l\u2019industrie pharmaceutique pratiquant la recherche qui fait les frais d\u2019\u00e9conomies douloureuses. Interpharma est n\u00e9anmoins dispos\u00e9e \u00e0 continuer de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2966,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[122],"class_list":["post-12256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-communique-de-presse"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique\" \/>\n<meta property=\"og:description\" content=\"La Commission de la sant\u00e9 du Conseil national s\u2019est prononc\u00e9e pour l\u2019introduction de mod\u00e8les d\u2019impact budg\u00e9taire pour les m\u00e9dicaments innovants. Dans le d\u00e9bat sur la ma\u00eetrise des co\u00fbts dans le syst\u00e8me de sant\u00e9, c\u2019est donc \u00e0 nouveau l\u2019industrie pharmaceutique pratiquant la recherche qui fait les frais d\u2019\u00e9conomies douloureuses. Interpharma est n\u00e9anmoins dispos\u00e9e \u00e0 continuer de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-18T15:34:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T09:32:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/09\/KP2-FR-1200x1200.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#\\\/schema\\\/person\\\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique\",\"datePublished\":\"2024-10-18T15:34:21+00:00\",\"dateModified\":\"2026-03-03T09:32:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/\"},\"wordCount\":804,\"publisher\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.interpharma.ch\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/KP2-FR.png\",\"keywords\":[\"Communiqu\u00e9 de presse\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/\",\"url\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/\",\"name\":\"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique - Interpharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.interpharma.ch\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/KP2-FR.png\",\"datePublished\":\"2024-10-18T15:34:21+00:00\",\"dateModified\":\"2026-03-03T09:32:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.interpharma.ch\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/KP2-FR.png\",\"contentUrl\":\"https:\\\/\\\/www.interpharma.ch\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/KP2-FR.png\",\"width\":1350,\"height\":1350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/blog\\\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.interpharma.ch\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#website\",\"url\":\"https:\\\/\\\/www.interpharma.ch\\\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.interpharma.ch\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\\\/\\\/www.interpharma.ch\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.interpharma.ch\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\\\/\\\/www.interpharma.ch\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/interpharma_ch\",\"https:\\\/\\\/ch.linkedin.com\\\/company\\\/interpharma\",\"https:\\\/\\\/www.instagram.com\\\/interpharma_ch\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.interpharma.ch\\\/#\\\/schema\\\/person\\\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\\\/\\\/www.interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique","og_description":"La Commission de la sant\u00e9 du Conseil national s\u2019est prononc\u00e9e pour l\u2019introduction de mod\u00e8les d\u2019impact budg\u00e9taire pour les m\u00e9dicaments innovants. Dans le d\u00e9bat sur la ma\u00eetrise des co\u00fbts dans le syst\u00e8me de sant\u00e9, c\u2019est donc \u00e0 nouveau l\u2019industrie pharmaceutique pratiquant la recherche qui fait les frais d\u2019\u00e9conomies douloureuses. Interpharma est n\u00e9anmoins dispos\u00e9e \u00e0 continuer de [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/","og_site_name":"Interpharma","article_published_time":"2024-10-18T15:34:21+00:00","article_modified_time":"2026-03-03T09:32:02+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/09\/KP2-FR-1200x1200.png","type":"image\/png"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique","datePublished":"2024-10-18T15:34:21+00:00","dateModified":"2026-03-03T09:32:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/"},"wordCount":804,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/09\/KP2-FR.png","keywords":["Communiqu\u00e9 de presse"],"inLanguage":"fr-FR","copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/","name":"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/09\/KP2-FR.png","datePublished":"2024-10-18T15:34:21+00:00","dateModified":"2026-03-03T09:32:02+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/09\/KP2-FR.png","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/09\/KP2-FR.png","width":1350,"height":1350},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-kostendaempfungspaket-2-erneut-einschneidende-sparmassnahmen-zulasten-der-pharmaindustriemedienmitteilung\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9 de presse: 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts: \u00e0 nouveau des \u00e9conomies douloureuses pour l\u2019industrie pharmaceutique"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/www.interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=12256"}],"version-history":[{"count":1,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12256\/revisions"}],"predecessor-version":[{"id":12257,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12256\/revisions\/12257"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/2966"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=12256"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=12256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}